Qingdao Marine Biomedical Research Institute

Qingdao Marine Biomedical Research Institute (QMBRI) is a leading Chinese research and development organization focused on the discovery and commercialization of marine-derived therapeutics. Established in 2013 through a partnership between the Ocean University of China and the Qingdao Municipal Government, the institute serves as the core of the Blue Pharmacy initiative. QMBRI specializes in marine oligosaccharides, glycoscience, and marine natural products, maintaining a robust pipeline targeting oncology, neurodegenerative diseases, and metabolic disorders. Notable achievements include the development of the marine-derived anti-tumor drug BG136 and foundational research for the Alzheimer's treatment sodium oligomannate. The institute operates an integrated platform that bridges basic marine science with industrial-scale pharmaceutical development and clinical application.